KRYS$332.292.38%7.74
After Hours: 328.00-4.29 -1.29%
Krystal Biotech Inc (KRYS)
Date: 2026-10-30 16:00O: 326.37H: 332.63L: 319.95C: 332.29Vol: 330.0k
Krystal Biotech Inc stock is traded at $332.29, with a volume of 330,014. It is up +2.38% in the last 24 hours and down -0.08% over the past month. Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Previous Close:
$324.55
Open:
$326.37
24h Volume:
330,014
Relative Volume:
1.30
Market Cap:
$9.84B
Revenue:
$417.30M
Net Income/Loss:
$225.03M
P/E Ratio:
44.41
EPS:
$7.48
Net Cash Flow:
$237.38M
1W Performance:
+6.67%
1M Performance:
-0.08%
6M Performance:
+26.70%
1Y Performance:
+75.74%
1-Day Range:
$319.95$332.63
1-Week Range:
$309.63$332.63
52-Week Range:
$184.02$382.54
Krystal Biotech Inc Stock (KRYS) Company Profile
Name
Krystal Biotech IncSector
HealthcareIndustry
BiotechnologyPhone
(412) 586-5830Address
2100 WHARTON STREET, PITTSBURGH, PA, USACompare KRYS vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRYS Krystal Biotech Inc | $332.29 | $9.84B | $417.30M | $225.03M | $237.38M | $7.48 |
 VRTX Vertex Pharmaceuticals Inc | $558.88 | $141.65B | $12.34B | $4.34B | $3.71B | $16.87 |
 REGN Regeneron Pharmaceuticals Inc | $927.89 | $95.53B | $14.92B | $4.42B | $3.79B | $41.04 |
 MRNA Moderna Inc | $221.72 | $88.52B | $2.23B | -$3.19B | -$1.60B | -$8.15 |
 ARGX Argen X Se Adr | $892.87 | $56.15B | $4.16B | $1.29B | $734.26M | $19.58 |
 ONC Beone Medicines Ltd Adr | $370.33 | $41.89B | $5.76B | $514.49M | $1.10B | $4.48 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
Krystal Biotech Inc Stock (KRYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Krystal Biotech Inc Stock (KRYS) Insider Trading
- SUMA KRISHNANSep 04 '26Director
- Transaction
- Proposed Sale
- Cost
- $371.47
- #Shares
- 25,000
- Value ($)
- 9,286,750
- #Shares Total
- 0
- Krishnan Krish SSep 04 '26President and CEO
- Transaction
- Sale
- Cost
- $359.32
- #Shares
- 25,000
- Value ($)
- 8,983,084
- #Shares Total
- 1,347,543
- KRISH KRISHNANSep 04 '26Director
- Transaction
- Proposed Sale
- Cost
- $371.47
- #Shares
- 25,000
- Value ($)
- 9,286,750
- #Shares Total
- 0
- Dino A. RossiAug 14 '26Director
- Transaction
- Proposed Sale
- Cost
- $332.27
- #Shares
- 25,000
- Value ($)
- 8,306,750
- #Shares Total
- 0
- ROSSI DINO AAug 14 '26Director
- Transaction
- Sale
- Cost
- $329.12
- #Shares
- 25,000
- Value ($)
- 8,227,953
- #Shares Total
- 50,000
- Thomas John CharlesJun 25 '26EVP, General Counsel
- Transaction
- Option Exercise
- Cost
- $179.25
- #Shares
- 1,000
- Value ($)
- 179,250
- #Shares Total
- 1,000
- Thomas John CharlesJun 25 '26Officer
- Transaction
- Proposed Sale
- Cost
- $347.27
- #Shares
- 1,000
- Value ($)
- 347,270
- #Shares Total
- 0
- Thomas John CharlesJun 25 '26EVP, General Counsel
- Transaction
- Sale
- Cost
- $347.27
- #Shares
- 1,000
- Value ($)
- 347,270
- #Shares Total
- 0
- Krishnan SumaJun 04 '26President, R&D
- Transaction
- Sale
- Cost
- $308.11
- #Shares
- 25,000
- Value ($)
- 7,702,825
- #Shares Total
- 1,378,155
- Krishnan Krish SJun 04 '26President and CEO
- Transaction
- Sale
- Cost
- $308.12
- #Shares
- 25,000
- Value ($)
- 7,702,984
- #Shares Total
- 1,450,253
